Vioguard blasts germs off keyboards
Hospital-associated infections are a growing concern for hospitals. Some 1.7 million people pick up infections each year while in hospitals. More than 99,000 die. While these infections may come from several sources, studies have shown that computer keyboards are a leading contributor. With the introduction of their first product, a self-sanitizing keyboard, Seattle-based Vioguard hopes to eliminate the keyboard as a vector of infection in hospitals.
Hospital-associated infections are a growing concern for hospitals. Some 1.7 million people pick up infections each year while in hospitals. More than 99,000 die. While these infections may come from several sources, studies have shown that computer keyboards are a leading contributor. With the introduction of their first product, a self-sanitizing keyboard, Seattle-based Vioguard hopes to eliminate the keyboard as a vector of infection in hospitals.
Vioguard’s keyboard is a “plug and go”, software free, automated device. At the end of each use the keyboard automatically slides into its enclosure where it is sanitized by two 25-watt germicidal UV lights. Studies have shown that these two lights kill 99.9% of organisms present on the surface. Due to the use of these germicidal lights, each user comes to a freshly cleaned, germ free keyboard.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
